CFR RECEPTOR ANTAGONISTS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA Russian patent published in 2020 - IPC A61K31/427 A61P5/38 

FIELD: medicine; therapy; endocrinology.

SUBSTANCE: present group of inventions concerns treating congenital hyperplasia of adrenal glands. That is ensured by administering an effective amount of CRF₁ receptor antagonist with a half-dissociation period of more than 50 minutes, specifically compound of 2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl-]N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo-[1,5-a]pyrimidin-7-amine (NBI-77860) or 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543).

EFFECT: this allows correcting the levels of hormones included in the "hypothalamic-pituitary axis", in particular 17-hydroxyprogesterone and ACTH, and thus providing normalization of androgen formation with using lower, more physiological doses of hydrocortisone, thereby reducing treatment-related side effects.

6 cl, 6 dwg, 2 tbl, 6 ex